The Ministry of Health signed a MoU with Takeda to provide home nursing for patients with primary immunodeficiency and hemophilia

This initiative comes within the framework of MoHAP's keenness to expand its partnership to make qualitative progress in healthcare, and to provide support services such as educating patients about their disease, their symptoms and how to use medications, to improve the quality of their lives

  

Dubai: The Ministry of Health and Prevention (MOHAP) signed a Memorandum of Understanding (MoU) with “Shire Export Services GmbH”, a subsidiary of Takeda Group and “Bayti Home Health Care” to provide home nursing for patients with Primary Immunodeficiency and Hemophilia who are finding it difficult to consult the medical center, with a view to improving patients' commitment to treatment according to the attending physician's plan, in implementation of the "Sawa" initiative to support patients.

His Excellency Dr. Amin Hussain Al Amiri, the Assistant Undersecretary for Public Health Policies and Licensing, signed on behalf of the Ministry of Health and Prevention, in presence of Dr. Ruqaya Al Bastaki, the Director of MoHAP’s Drug Department, while Mr. Takafumi Horri, the General Manager for the Middle East, signed on behalf of "Shire Export Services", a subsidiary of Takeda Group, and
Mr. Rajeev Nikani, the Executive Director of "Bayti Home Health Care" signed on behalf of Bayti, in the presence of His Excellency Akihiko Nakajima; Ambassador Extraordinary and Plenipotentiary of Japan.

Expanding Partnerships

This initiative comes within the framework of MoHAP’s keenness to expand its partnership to make qualitative progress in healthcare, and to provide support services such as educating patients about their disease, their symptoms and how to use medications, to improve the quality of their lives. "Sawa" initiative aims to provide nurses and doctors specialized and licensed in home healthcare, who will offer support services to patients with primary immunodeficiency or hemophilia, by providing them with a detailed explanation about the medication system and the method of injection or its usage, as prescribed by the attending physician, in addition to following up the patient’s condition, ensuring the patient’s commitment to treatment, the monitoring of any defect, and the communication of the patient's condition to the attending physician.

His Excellency Akihiko Nakajima; Ambassador Extraordinary and Plenipotentiary of Japan has pointed out that the joint vision and joint cooperation strategy existing between the United Arab Emirates and Japan under a framework named “Comprehensive Strategic Partnership Initiative for Future Cooperation”.

In this context, it is important to build up tangible results in each area, “I’m very proud that the one of the biggest medical companies in Japan and the MOHAP collaborate in the field of rare diseases and Home Care Program”.

Providing Services to Empower Patients

Mr. Takafumi Hori commended the openness of the MoHAP in cooperating with and supporting the endeavors to provide home healthcare services to patients in the UAE. Moreover, he pointed out that the agreement seeks, in cooperation with Bayti Home Health Care, to empower patients with primary immunodeficiency or hemophilia, who are finding it difficult to consult the medical center, to access home nursing.

Coordination and Follow-up

The agreement has established the program of "Bayti Home Health Care" in coordination with doctors, hospitals and local health authorities, and the provision of nurses specialized and licensed in home healthcare, in addition to following up on patients who are being treated, and the progress of their condition in the program.

-Ends-

About Takeda Pharmaceuticals

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com 

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases